SLC5A2 and type 2 diabetes mellitus: After verifying the predictive performance of the SGLT2 inhibitor PBPK model in healthy subjects and patients with T2DM and normal renal function, the PBPK model was extrapolated to patients with T2DM and renal insufficiency by adjusting the GFR and physiological parameters of virtual T2DM patients according to clinical-patient mean values.